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Background: Anti-glomerular basement membrane (GBM) glomerulonephritis and systemic lupus erythematosus
(SLE) are both disorders of the immune system; however, they are known as distinct diseases. Till now no clinical
evidence suggests the genetic relationship between these two diseases. Herein, we present two identical twins;
one was diagnosed as anti-GBM glomerulonephritis, the other SLE. This is the first clinical report on the genetic
relationship between these two diseases.
Case presentation: A 25-year-old female was admitted complaining of intermittent gross hematuria for 6 months
and elevated serum creatinine for 1 month. She denied hemoptysis. Laboratory examinations showed hemoglobin 7.4
g/dL, serum creatinine 7.15 mg/dL and albumin 2.8 g/dL. Urinalysis showed hematuria (484 RBCs per high-power field)
and proteinuria 4+. Antinuclear antibody, complement levels and ANCAs were all normal. Renal ultrasound showed
normal-sized kidneys without obstruction or masses. Serum anti-GBM antibody assay showed 119.70 RU/mL
(normal range, <20 RU/mL). Chest X-ray was normal. She was diagnosed as anti-GBM glomerulonephritis and received
plasma exchange (2000-3000 ml plasma/exchange, 5 turns), methylprednisolone 0.5 g for three days, plus
cyclophosphamide. Although serum anti-GBM antibodies decreased gradually to a normal range, her renal
function did not improve. One month later, her identical twin sister was diagnosed as SLE based on malar
erythema, arthralgia, antinuclear antibody positive with liter 1:1000, and Anti-Smith (Sm) antibody ++. Anti-GBM antibody
and complements were within normal ranges. Further study showed these twins were HLA-DRB1*1501 homozygotes.
Conclusion: The presence of identical twins having anti-GBM nephritis and SLE respectively provides clinical evidence to
support that anti-GBM nephritis and lupus may share a common genetic background to some extent, while environment
may contribute to disease evolution in part.
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Lupus is a prototypic autoimmune disease and pathogen-
esis involves genetic predisposition and environmental
conditions. Its highest reported concordance rate in
monozygotic twins is up to 57% [1]. Anti-GBM nephritis
is also an autoimmune disease, but is much more rare and
with a lower incidence compared to lupus. This disease
can also occur in siblings and sets of identical twins [2].
However, there is no reported case of identical twins
suffering from anti-GBM nephritis and lupus separately.* Correspondence: hzxawy@scu.edu.cn
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reproduction in any medium, provided the orWe report a 25-year-old female developing anti-GBM
nephritis, and her identical twin sister developing systemic
lupus erythymatosus (SLE). Their HLA genotypes were
both homozygous for HLA-DRB1*1501.
Case presentation
A 25-year-old female was admitted to our hospital
complaining of intermittent gross hematuria for 6 months
and elevated serum creatinine for 1 month. She was in
good health until November of 2009, when she noticed
gross hematuria without fever, dysuria, frequency, urgency,
and suprapubic pain. Hematuria was noted every month,
but she did not pay it any attention. In March of 2010, she
noticed edema of her lower extremities and went to aThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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7.28 g/24 h, RBC 823 per high-power field, Hemoglobin
8.5 g/dl, serum albumin 3.1 g/dL, creatinine 4.98 mg/dL.
One month later, she was transferred to our hospital. On
physical examination, she presented with a pale face
and edema of the lower extremities. Blood pressure
was 150/100 mmHg, Hemoglobin was 7.4 g/dL, while
the leukocyte and platelet counts were normal. Serum
creatinine was 7.15 mg/dL and albumin 2.8 g/dL. Urinalysis
showed hematuria (484 RBCs per high-power field)
and proteinuria 4+. Antinuclear antibody, complement
levels and ANCAs were all negative or normal. Renal
ultrasound showed normal-sized kidneys without obstruc-
tion or masses. Serum anti-GBM antibody assay by enzyme
immunoassays (ELISA, EA 1251-9601 G, EUROIMMUN
Medical Laboratory Diagnostics Co.,Ltd) showed 119.70
RU/mL (normal range, <20 RU/mL). She became weaker
and serum creatinine gradually elevated to 9.3 mg/dL while
urine output decreased to 300 ml/day. No hemoptysis
developed and chest X-ray was normal.
The patient was diagnosed with anti-GBM nephritis,
then treated with plasma exchange (2000-3000 ml
plasma/exchange) plus hemodialysis every other day for
5 times, methylprednisolone 0.5 g for three days, plus
cyclophosphamide 1 g for pulse infusion. Then her
medications were shifted to oral prednisone 50 mg/day.
2 weeks later, MP and CTX were administered again.
Although serum anti-GBM antibody titer decreased grad-
ually to normal, serum creatinine and urine outcome did
not improve (Figure 1). Hemodialysis therapy continued.
Surprisingly, her identical twin sister came to our
hospital complaining of malar erythema and arthralgiaFigure 1 Changes of serum creatinine, anti-GBM antibody and therap
line: serum anti-GBM antibody (RU/mL); Right Y-axis: squares: dashed line: s
MP: methylprednisolone, CTX: cyclophosphamide, HD: hemodialysis.one month later. No hemoptysis, photosensitivity, edema
and hematuria were recorded. Physical examination
showed butterfly rash. No edema, oral ulcer, fever and hair
loss. Hemoglobin was 13.1 g/dL, WBC was 5.46x109/L,
platelet was 116x109/L, serum albumin was 4.17 g/dL and
creatinine was 0.56 mg/dL. Urine protein was 0.1 g/24 h,
No microscopic hematuria was revealed. Antinuclear
antibody was positive with liter 1:1000, Smith (Sm)
antibody ++, dsDNA antibody negative, ANCA negative.
Anti-GBM antibody and complements were within their
normal ranges (C3 1.07 g/L, C4 0.139 g/L). Based on the
diagnostic criteria of SLE in 1982 of American College of
Rheumatology, she was diagnosed as SLE. Oral prednisone
40 mg/day was initiated and tapered regularly with allevi-
ation of her rash and arthralgia. Two years later, malar
erythema relapsed with lowered C3 0.652 g/L. Prednisone
was increased to 40 mg/day combined with leflunomide
20 mg/day and hydroxychloroquine 400 mg/day. Her rash
faded again. At the end of follow up, serum creatinine
was 0.71 mg/dL, serum albumin was 4.18 g/dL, hemoglobin
was 14.2 g/dL, WBC was 4.25x109/L, platelet was 114x109/L,
anti-GBM antibody was still within normal range.
Considering HLA-DRB1*1501 alleles are associated
with susceptibility to anti-GBM nephritis and lupus, we
analyzed HLA-DRB1 alleles in these two sisters, and they
were both HLA-DRB1*1501 homozygotes.
Conclusions
Anti-GBM nephritis is a rare autoimmune disorder
characterized by elevated serum anti-GBM antibodies
and rapidly progressive glomerulonephritis. Renal biopsy
reveals crescent glomerulonephritis with linear IgG deposity in the patient with anti-GBM nephritis. Left Y-axis: rhombus: solid
erum creatinine concentration (mg/dL). PE: plasma exchange,
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present, this condition is called Goodpasture’s Syndrome
[3]. The first patient presented gross hematuria and rapid
deterioration of renal function with significantly elevated
anti-GBM antibodies and negative ANCA and ANA.
Although renal biopsy was not conducted, anti-GBM
nephritis was diagnosed based on elevated anti-GBM
antibody and clinical manifestations of rapidly progressive
glomerulonephritis. Although plasma exchange and pulse
treatment of MP and CTX had been applied, she was still
dialysis-dependent. The outcomes of anti-GBM nephritis
depend on renal function at presentation and percent-
age of crescents on renal biopsy [4]. Considering she
was dialysis-dependent and serum creatinine exceeded
9 mg/dL at presentation, chance of renal survival should
be less than 8% [4]. Interestingly,her identical twin sister
developed lupus with negative anti-GBM antibody later.
Till now, it has not been reported that identical twins
developed either lupus or anti-GBM nephritis.
There are evidently differences in pathogenesis, clinical
manifestations and outcomes between anti-GBM glomer-
ulonephritis and lupus. For example, anti-GBM nephritis
is associated with anti-GBM antibody and rarely relapses,
while lupus involves many antibodies including ANA,
dsDNA, Smith(Sm) antibody, and is a life-long disorder
that may relapse. It has long been believed that anti-GBM
nephritis is different from other autoimmune disorders.
Recently, there is evidence suggesting that there is
relationship between lupus and anti-GBM nephritis. C-H
Li et al. found that anti-GBM antibody was detected in 14
(8.9%) of 157 patients with SLE [5]. All of the 14 patients
developed lupus nephritis; ten of them reached the criteria
for crescentic glomerulonephritis and five of them
were diagnosed as Goodpasture’s disease. A few cases
also showed coexistence of anti-GBM glomerulonephritis
and lupus [6,7]. It was suggested that ongoing glomerular
inflammation may change GBM structure, triggering an
autoimmune reaction by exposing or modifying antigens,
as proposed for the association between anti-GBM
disease and ANCA glomerulonephritis [8]. However,
identification of twins diagnosed as anti-GBM glomerune-
phritis and lupus respectively could not be attributed to this
hypothesis. It seems that some genetic connection may
exist between these two diseases.
Human leukocyte antigen (HLA), which plays an
important role in immune responses, consists of the
class I and class II molecules. Class II molecules are
required for the presentation of antigens to T cell receptors
and contribute to the production of specific antibodies.
Genetic defects in self-tolerance can be triggered by
reduced or altered expression of HLA molecules, which
may aggravate the progression of different antoimmune
diseases [9]. Genes in the HLA complex are among the
strongest predisposing genetic factors. HLA-DRB1*1501has been associated with susceptibility to anti-GBM
disease. The frequency of HLA-DRB1*1501 in anti-GBM
antibody-positive Japanese and Chinese patients was
significantly higher than controls (36/88 vs 64/400,
P = 1.597 × 10−7, in China) [10,11]. HLA-DRB1*1501
alleles were also significant risk factors for SLE [9,12].
DRB1*1501/DQB1*0602 was identified as one of three
microsatellite-inferred risk haplotypes in European lupus
families [13]. HLA-DRB1*1501 allele are strongly associ-
ated with multiple sclerosis in African-American [14]. The
mechanism underlying HLA association with autoimmune
diseases is not clearly understood until now. Although
it is difficult to define HLA-DRB1*1501 as a molecular
biomarker of anti-GBM nephritis or lupus, the fact that
these identical twins were both HLA-DRB1*1501 homozy-
gotes supports the possible association of this allele with
anti-GBM and lupus.
The latest research shows that out of about 25 dif-
ferent molecules in anti-GBM nephritis mouse model
and spontaneous lupus nephritis (SLN), all influenced
both diseases concordantly, including complement-and
FcR-dependent activation of resident renal cells and infil-
trating leukocytes, proinflammatory mediators initially, and
profibrotic molecules [15]. Since SLN in mouse models
takes 6-12 months to manifest, the experimental anti-GBM
nephritis model has been used as a useful tool to unravel
the molecular basis of SLN.
It is exciting that kallikrein genes may be the common
candidate genes for lupus and anti-GBM nephritis in
animal models [16]. Briefly, some murine strains, including
NZW, DBA/1, are highly sensitive to experimental
anti-GBM nephritis, while other strains such as C57BL/6
(B6) are resistant [17]. A microarray-based transcriptomic
analysis revealed that the kallikrein (KLK) gene family
may be the key to produce these differences between these
strains [16]. The tissue kallikrein gene cluster is located
within the Sle3 interval [18], one of potential pathogenic
loci in SLE. B6. Sle3z mice (bearing the NZM2410/NZM-
derived “z” allele of Sle3 on the relatively normal B6 back-
ground), exhibited increased susceptibility to experimental
anti-GBM-induced nephritis compared with wide-type
B6 [16]. Delivery of klk1 encoding KLK1(the principal
kinin-generating enzyme) to B6. Sle3 congenics amelio-
rated anti-GBM-induced nephritis [19]. Interestingly, B6.
NZMc1|c7 mice (bicongenic for Sle1 and Sle3) could
produce significantly elevated glomerular-binding auto-
antibodies compared with B6 [20]. These findings indicated
that kallikreins play an important role in these diseases, and
could constitute a potential candidate genes for anti-GBM
nephritis and SLN.
Although evidence mentioned above demonstrates
similarities of genetic backgrounds between lupus and
anti-GBM nephritis, after all, the huge differences of
their clinical features still exist. Why would these twins
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different diseases respectively? Although genetic pre-
disposition plays an important role in these diseases,
it is generally accepted that environmental factors
modulate the susceptibility, in part, through epigenetic
changes. The concordance rate of lupus in identical twins is
greater than in the general population, but it is still
incomplete [1,21,22]. Many epidemiologic and environmen-
tal elements such as ethnicity, gender, hormonal exposure,
UV radiation, pregnancy, smoking habits, and viral expo-
sures are thought to influence these phenotypic variations.
Recent studies showed that epigenetic alterations play an
important role on the pathogenesis of SLE, including the
global loss of DNA methylation and altered patterns of
histone modifications [23]. Although anti-GBM glomerulo-
nephritis may occur in siblings and sets of identical twins
[2], there are few epigenetic study of this disease because of
the rarity. Environmental factors including exposure to
hydrocarbons and smoking have been thought to associate
with the onset and progression of anti-GBM glomerulo-
nephritis, which is different from SLE. Because pathogenic
mechanisms involving the onset and progression of these
diseases are far from clear, although the twins seemed to
grow up in the same environment and shared the same
genetic background, it is possible that some unknown
environmental factors triggered the onsets of diverse
diseases. Although the girl suffering from SLE has
normal serum anti-GBM antibody, she may also develop
anti-GBM glomerulonephritis in the future under some
situation, and vice versa.
We present two identical twins that developed
anti-GBM nephritis and lupus respectively, which supports
a connection between these diseases, which need to be
investigated further. Environmental factors may contribute
to final clinical differences.Consent
Written informed consent was obtained from both patients
for publication of this Case report and any accompanying
images. A copy of the written content is available for
review by the Editor of this journal.
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